TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in neurological status measured by NIHSS after hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neurological status measured by Modified Rankin Scale after hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neurological status measured by NIHSS after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neurological status measured by Modified Rankin Scale after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Technical Success of Tumor Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Local Tumor Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relationship between ICG and MCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationship between pro and anticoagulant proteins levels and endothelial markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of the enteroendocrine cell population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Measured Glomerular Filtration Rate (mGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of hematological and biochemical laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pancreatic fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MASP-2 concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV/AIDS-related knowledge, attitude, behaviour, practices and skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: obesity-related awareness, attitude and skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: nutrition-related awareness, attitude, behaviour and skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: physical activity-related awareness, attitude, behaviour and skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: child-parent communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Relative Attachment Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to disease self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants With Adverse Experiences During Weeks 0-12
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Blood Pressure Measurements to Week 12 and Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrocardiogram (ECG) Results At Weeks 0, 12, and 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incremental Area Under the triacylglycerol Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of overall Grade >=3 Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of anticipated AIC100 CAR T Cell related AEs, SAEs and adverse events of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Serial changes in plasma and urine metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serial changes in plasma and urine TMAO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural Course of Long QT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in sensory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of water consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total liquid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of interscalene nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sleep patterns
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: static tactile 2-point-discrimination threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of RBD Episodes in One Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Severe RBD Episodes in One Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in American Orthopedic Foot and Ankle Society Forefoot Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of SMBG for clinical decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative cognitive change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum change in plasma norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption measured in morphine equivalents
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of ketamine side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline in findings on physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in key ECG findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in safety laboratory tests (hematology, chemistry, urinalysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes from baseline in vital sign measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Alive and Progression-free at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Condom use at last sex
Endpoint domain: Adverse events/effects
Primary endpoint: Learning Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with radiological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of doses of pain medication used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain scale based on the faces pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Text messages read by HV clients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Home Visitor Adherence to MB-TXT protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Client perceived utility and comprehension of text messages
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Radiographic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of verbal vs written teaching
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: 30-second chair stand test (30s-CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in HbA1c at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in brain activity as assessed by fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose (MTD) of everolimus
Endpoint domain: Adverse events/effects
Primary endpoint: Medication adherence - Pill Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence - Plasma Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence - Clinician Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objectively Measured Salivary Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objectively Measured Percentage Salivary Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (complete / partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for Heart Disease and Strokes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary patency of claudicant patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Salvage limb rate (for CLI patients)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of Potentially Inappropriate Prescriptions (PIPs) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clozapine steady state plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients receiving at least 70% of scheduled treatment fractions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number Of Participants Experiencing Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Participants Experiencing Grade 3 Or 4 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Participants Experiencing AEs Leading To Discontinuation From The Study
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of inflammatory markers and hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Choroidal & retinal morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in energy levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of patients reporting gastrointestinal effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of shakes consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of cardiovascular affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cross-sectional area of internal jugular vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: abstinence from smoking in the last 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Nasal Polyp Score (NPS) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive conversion rate evaluation (6 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: antibody titer evaluation (6 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: positive conversion rate evaluation (12 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: antibody titer evaluation (12 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tolerability and safety of the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Silver levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Comfort Questionnaire (GCQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ovulation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline child safety at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline child physical health at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline adult survivor social and emotional abilities at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: alveolar bone vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Carotid intimal medial thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 10-year cardiovascular risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recall rate
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Deep-vein thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Non-fatal pulmonary embolism (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean length of hospital stay in days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in modified pulmonary index score (MPIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Appearance of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Expanded Disability Status Scale (EDSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Syndrome Z-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number, severity and duration of organ failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of esCCO and Picco
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Typical alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist Flexor Muscle Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Post-operative oral analgesic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in ILK from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in spectrin from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ezrin from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in S100A9 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroprotected Subjects Against Vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With a Booster Response to Pertussis Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Hemoglobin A1C Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of dental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Alpha-Synuclein Inclusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of solicited and unsolicited symptoms and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody levels for relevant immunological indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Cognitive Functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Cognitive Performance Questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Antiplatelet effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in prescription of antiplatelet therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Binocular uncorrected visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in Rey Auditory Verbal Learning Test (RAVLT) total learning scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Increase in Rey Auditory Verbal Learning Test (RAVLT) recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Levels of Differential Proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ox-PAQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of digital sedation in colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of colonoscopy using digital sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD diagnosis and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in disease-related symptoms over time assessed by the Lafora Disease Performance Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure frequency, (by type and severity) as recorded in seizure diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL), as measured by QoL in Epilepsy for Adolescents (QOLIE-AD-48) by age at Screening
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Natural course of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in score on Word Attack subtest
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Passage Comprehension subtest
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Word Reading subtest
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Spelling subtest
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Test of Silent Reading Speed and Efficiency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of grade 3-4 diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Time to the First Occurrence of Composite Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the First Occurrence of Primary Clinical Event (Expanded Endpoint)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients assigned to treatment modality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability assessed by adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Bacteriologic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Total Left Ventricular Endocardial Border Delineation (LV EBD) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Adequate Left Ventricular Opacification (LVO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of risk factors associated with lung transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain measurement using CHEOPS and FLACC scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator Assessment of Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of All AP Signs and Clinical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of pancreatic ductal adenocarcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Establishment and characterization of patient-derived cancer xenografts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient responder rate (loss of less than 15 letters of visual acuity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient responder rate (loss of fewer than 30 letters of visual acuity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 1st clinically significant ET related event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse wave velocity (arterial stiffness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes